Adults With Type 2 Diabetes Lost Almost 20 Percent of Their Weight on Retatrutide Lilly released findings from two separate phase 3 clinical trials on Thursday, the first being TRIUMPH-2, which included about 1,150 adults who were overweight or had obesity and type 2 diabetes
Dosing with compounded GLP-1 drugs can be confusing, Simonetti says
The relationship between visceral fat loss and metabolic health means that many of the cardiometabolic improvements continue advancing even as the rate of weight loss begins to gradually slow
Emerging evidence suggests that innovative diabetes therapies, particularly GLP-1 RAs and SGLT2 inhibitors, may offer neuroprotective benefits beyond glycemic control, through their favorable effects on metabolic regulation, inflammation, oxidative stress and neuronal survival
Median copays: $90 semaglutide, $80 tirzepatide
Liraglutide has a half-life of 13 hours in humans and semaglutide has a half-life of 160 hours (35)